Effect of Sacubitril-Valsartan on Cardiac Structure and Function
Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
Phase:
PHASE3
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
sacubitril and valsartan sodium hydrate drug combination